Delineation of the role of platelet-activating factor in the immunoglobulin G2 antibody response.
Localized aggressive periodontitis (LAgP) is a chronic inflammatory disease characterized by severe destruction of periodontal tissues surrounding the first molars and incisors. LAgP subjects produce large amounts of immunoglobulin G2 (IgG2) antibody against oral pathogens, and this response is inversely correlated with the severity of disease. We previously demonstrated that platelet-activating factor (PAF) is required for optimal IgG2 responses. The present investigation was designed to determine the mechanism of IgG2 induction by PAF. Exogenous PAF acetylhydrolase suppressed approximately 80% of pokeweed mitogen-stimulated IgG2 production, confirming that PAF is essential for optimal responses. PAF-activated leukocytes produced gamma interferon (IFN-gamma), a Th1 cytokine that has been associated with IgG2 responses in previous studies. The monocyte-derived cytokines interleukin-12 (IL-12) and IL-18 are upstream of IFN-gamma production, and IgG2 production was suppressed by neutralizing antibodies against these proteins. In addition, PAF induced monocyte-derived dendritic cells (DC) but not macrophages (MPhi) to secrete IL-12 and IL-18. This observation was interesting because monocyte differentiation in LAgP subjects is skewed to the DC phenotype. Although other investigators have implicated IFN-gamma in IgG2 production, its precise role in this response is controversial. Our studies suggest that IFN-gamma induces isotype switching to IgG2 but only in concert with the Th2 cytokine IL-4. Thus, it appears that the unique PAF metabolism of LAgP monocytes or DC promotes Th1 responses that are essential for optimal IgG2 antibody production. As IgG2 antibodies opsonize oral bacteria and promote their clearance and destruction, these alterations in PAF metabolism may be essential for limiting disease severity in LAgP patients.
Al-Darmaki
Salma
S
Clinical Research Center for Periodontal Diseases, Virginia Commonwealth University, Richmond, Virginia, USA.
Knightshead
Kandi
K
Ishihara
Yuichi
Y
Best
Al
A
Schenkein
Harvey A
HA
Tew
John G
JG
Barbour
Suzanne E
SE
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000378:metabolism / Q000494:pharmacology; D000328:Adult; D001402:B-Lymphocytes / Q000276:immunology; D016207:Cytokines / Q000276:immunology*; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology; D006801:Humans; D017578:Immunoglobulin Class Switching / Q000187:drug effects / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology*; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000276:immunology; D015847:Interleukin-4 / Q000276:immunology; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology; D008213:Lymphocyte Activation; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D010510:Periodontal Diseases / Q000276:immunology*; D010972:Platelet Activating Factor / Q000276:immunology* / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction
D016207:Cytokines; D007074:Immunoglobulin G; D010972:Platelet Activating Factor; D015847:Interleukin-4; D007371:Interferon-gamma; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase